1.Application of Botulinum Toxin in Disorders of the Gastrointestinal Tract.
Korean Journal of Gastrointestinal Motility 2003;9(1):1-5
No abstract available.
Botulinum Toxins*
;
Gastrointestinal Tract*
2.Steroid Treatment of Autoimmune Pancreatitis.
The Korean Journal of Gastroenterology 2006;47(6):467-469
No abstract availble.
Autoimmune Diseases/*drug therapy
;
Glucocorticoids/*therapeutic use
;
Humans
;
Pancreatitis, Chronic/*drug therapy/immunology
3.Molecular Diagnosis and Tumor Markers in Pancreatic Cancer.
Korean Journal of Hepato-Biliary-Pancreatic Surgery 2004;8(2):69-75
Pancreatic cancer is a devastating disease with a fatal prognosis due to late diagnosis. Current imaging studies are inadequate for early detection and CA 19-9, the best tumor marker thus far, has low sensitivity in small pancreatic cancer, so the use of new markers is our most promising approach. Activation of the proto-oncogene K-ras and inactivation of the tumor suppressor genes p53, p16 and SMAD4 are characteristics for pancreatic cancer. K-ras mutation can be detected from pancreatic juice in 55~79% of patients with pancreatic cancer but can occur in the setting of chronic pancreatitis up to 32%. Telomerase activity in pancreatic juice can be used to distinguish between cancer and pancreatitis. The progression model of pancreatic cancer proposes that pancreatic intraepithelial neoplasia is the pre-cancerous lesion and this model is important for developing screening tools to detect early curable cancer. Pancreatic cancer harbors aberrant methylation of many cancer-related genes and detection of DNA hypermethylation by methylation specific PCR is attractive new candidate suitable for early detection. Recent large- scale gene expression studies can be done using cDNA and oligonucleotide microarrays and serial analysis of gene expression. Hundreds of overexpressed genes were already identified in pancreatic cancer. Large-scale analysis of proteins in biologic samples is possible by proteomics which has been applied to discovery proteins that could be used as potential markers. It is hoped that the understanding of genetic alterations and development of high throughput technologies will lead to the rapid discovery of biomarkers that will save lives by enabling aggressive therapy at the early stage.
Biomarkers
;
Carcinoma, Pancreatic Ductal
;
Delayed Diagnosis
;
Diagnosis*
;
DNA
;
DNA, Complementary
;
Gene Expression
;
Genes, Tumor Suppressor
;
Hope
;
Humans
;
Mass Screening
;
Methylation
;
Molecular Biology
;
Oligonucleotide Array Sequence Analysis
;
Pancreatic Juice
;
Pancreatic Neoplasms*
;
Pancreatitis
;
Pancreatitis, Chronic
;
Polymerase Chain Reaction
;
Prognosis
;
Proteomics
;
Proto-Oncogenes
;
Telomerase
;
Biomarkers, Tumor*
4.The epidemiology and risk factors of hilar cholangiocarcinoma.
Korean Journal of Medicine 2010;79(6):593-596
A hilar cholangiocarcinoma is a cholangiocarcinoma occurring at the confluence of the right and left hepatic bile ducts which is called as Klatskin tumor. Because hilar cholangiocarcinoma is the most common form of extrahepatic bile duct cancer (EBDC), the epidemiology and risk factors of hilar cholangiocarcinoma are similar to those of EBDC. In Korea, overall incidence of EBDC is 5.1/100,000 individuals without a significant change during past 10 years. Most of cases occur in patients over the age of 50 and the incidence is 1.78 times higher in men than women. The etiology of EBDC has not been clearly defined. A number of pathologic conditions, however, resulting in either acute or chronic biliary tract epithelial injury may predispose to malignant change. Chronic biliary tract parasitic infection, such as Clonorchis sinensis and Opisthorchis viverrini, has been identified as a risk factor of EBDC and hilar cholangiocarcinoma. Other clear risk factors of EBDC are primary sclerosing cholangitis and choledochal cyst. However, there are no enough evidences whether primary sclerosing cholangitis and choledochal cyst are the definite risk factors of hilar cholangiocarcinoma or not.
Bile Ducts
;
Bile Ducts, Extrahepatic
;
Biliary Tract
;
Cholangiocarcinoma
;
Cholangitis, Sclerosing
;
Choledochal Cyst
;
Clonorchis sinensis
;
Female
;
Humans
;
Incidence
;
Klatskin's Tumor
;
Korea
;
Male
;
Opisthorchis
;
Risk Factors
5.Correction of Erratum.
The Korean Journal of Gastroenterology 2010;55(1):80-80
In the recently published paper, there was a typo in the affiliation of the author. The word Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea was incorrectly spelled as Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. We hereby publish the correct affiliation as follows: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
6.Correction of Erratum.
The Korean Journal of Gastroenterology 2010;55(1):80-80
In the recently published paper, there was a typo in the affiliation of the author. The word Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea was incorrectly spelled as Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. We hereby publish the correct affiliation as follows: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
7.Metal Stenting in Benign Biliary Strictures.
Clinical Endoscopy 2014;47(1):5-6
No abstract available.
Constriction, Pathologic*
;
Stents*
8.Percutaneous Approach for Removal of Difficult Common Bile Duct Stones.
Clinical Endoscopy 2013;46(1):3-4
No abstract available.
Common Bile Duct
9.Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer.
The Korean Journal of Gastroenterology 2015;66(3):150-153
Pancreatic adenocarcinoma is one of the fatalist malignancies. A large proportion of patients are diagnosed with unresectable stage pancreatic cancer at the time of presentation. Gemcitabine is a standard chemotherapeutic agent since 1997, but survival benefit is not satisfactory. Recent clinical study proved that several new combination chemotherapy regimens are superior to gemcitabine single chemotherapy and extended overall survival. However, its prognosis still remains grim. Current research is taking a multidirectional approach in the hope of developing more effective treatments. This article reviews the major clinical trial data that is the basis for the current chemotherapy regimens used as first- and second-line treatments for advanced pancreatic adenocarcinoma. This article also reviews the current ongoing clinical trials, which include the use of molecular targeting agents and immune therapies.
Adenocarcinoma/*drug therapy/pathology
;
Antimetabolites, Antineoplastic/therapeutic use
;
Antineoplastic Agents/therapeutic use
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Deoxycytidine/analogs & derivatives/therapeutic use
;
Humans
;
Immunotherapy
;
Pancreatic Neoplasms/*drug therapy/pathology
;
Protein Kinase Inhibitors/therapeutic use
10.The Early Detection of Pancreatic Cancer: Whom and How?.
Korean Journal of Pancreas and Biliary Tract 2015;20(4):198-203
The 5-year survival rate of pancreatic cancer is extremely low till now, because resectable cases are less than 20% and 5-year survival rate after surgical resection is only 10-20%. Early detection and curative surgery are important to prolong the survival which was well proved by colon cancer screening test in general population. However, screening test for general population can not prove the survival benefit in pancreatic cancer. So, many studies were performed for the development of screening strategies in high-risk groups of pancreatic cancer. The following were current candidates for screening: first-degree relatives of patients with pancreatic cancer from a familial pancreatic cancer kindred with at least two affected first-degree relatives; patients with Peutz-Jeghers syndrome; and p16, BRCA2 and hereditary non-polyposis colorectal cancer mutation carriers with > or = 1 affected first-degree relative. The recommended screening tests are endoscopic ultrasonography and magnetic resonance cholangiopancreatography. Screening is recommended at age 50 or 10 year earlier than the onset age of pancreatic cancer among family. However, the screening interval is not established and there is great disagreement as to which screening abnormalities were of sufficient concern to for surgery to be recommended.
Age of Onset
;
Cholangiopancreatography, Magnetic Resonance
;
Colonic Neoplasms
;
Colorectal Neoplasms
;
Early Detection of Cancer
;
Early Diagnosis
;
Endosonography
;
Humans
;
Mass Screening
;
Pancreatic Neoplasms*
;
Peutz-Jeghers Syndrome
;
Survival Rate